ArticleEuropean journal of nuclear medicine and molecular imaging2026
Comparative performance of
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic performance of [¹¹C]methionine (MET) PET/CT for preoperative localisation in primary hyperparathyroidism (PHPT) with negative or inconclusive first-line imaging, and to compare it with [¹¹C]choline (CHO) PET/CT in a head-to-head analysis, focusing on determinants of adenoma detectability.
methodsFifty-one patients with biochemically confirmed PHPT underwent MET PET/CT following inconclusive conventional imaging. In a subgroup of 25 patients, CHO PET/CT was also performed. Imaging findings were correlated with surgical and histopathological results. Detection rates and positive predictive values (PPV) were calculated, and semiquantitative parameters, including standardized uptake value (SUV) and lesion-to-background ratio (LBR), were analysed. Associations between PET findings, biochemical markers, and adenoma weight were explored.
resultsMET PET/CT achieved a patient-based detection rate of 76.5% with a PPV of 88.2%. In the head-to-head subgroup, CHO detected more lesions than MET (27 vs. 14; p = 0.0025) and identified all histologically confirmed adenomas, with comparable PPVs (90.0% vs. 77.8%). CHO demonstrated significantly higher SUV and LBR values. Adenoma weight was significantly associated with PET findings: MET-positive adenomas were significantly heavier than MET-negative adenomas, whereas CHO maintained high lesion detection even in adenomas weighing 0.5 g or less. Additionally, a trend towards higher uptake with increasing PTH and calcium levels was observed for CHO SUVmax.
conclusionAdenoma weight appears to be a major determinant of PET detectability in PHPT. The ability of CHO PET/CT to detect adenomas weighing 0.5 g or less, which may remain occult on MET, provides a plausible explanation for its superior lesion detection, while both tracers maintain a high positive predictive value. These findings further support the use of choline-based PET imaging in patients with inconclusive first-line studies.
Indexed as
Identifiers
42595800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.